Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
Crossref DOI link: https://doi.org/10.1007/s11010-017-3084-z
Published Online: 2017-06-05
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sau, Samaresh
Mondal, Sujan Kumar
Kashaw, Sushil K.
Iyer, Arun K.
Banerjee, Rajkumar
Funding for this research was provided by:
CSIR Network Project grant (CSC0302, BSC0123)
License valid from 2017-06-05